Skip to main content

Advertisement

SpringerLink
Log in

Excess mortality for patients with residual disease following resection of pituitary adenomas

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

The importance of achieving tumor control in pituitary adenoma surgery is not entirely established. This manuscript reviews the literature linking residual pituitary tumor and hormonal hypersecretion to increases in long term mortality. When possible, we utilized meta-analysis methods to estimate a pooled standardized mortality ratio (SMR), which relates the risk of mortality for a cohort of patients compared to a similar age and gender matched cohort in the general population, for patients with endocrinologic evidence of residual disease. When this was not possible, we review the existing literature in the results and discussion section of this review. We identified 10 articles regarding acromegaly and three articles regarding Cushing’s disease which presented SMR data for adult patients undergoing transphenoidal surgery with data divided into subgroups based on post-operative growth hormone levels. Using growth hormone levels of 2.5 μg/l as a cutoff, the mortality rate ratio was 1.83 (95% CI = 1.03–3.24) for patients with persistent acromegaly. Similarly, patients with persistent Cushing’s disease experienced a marked increase in mortality rate ratio compared to those experiencing initial cure (mortality rate ratio = 3.25 (95% CI = 1.54–6.84). For other tumor subtypes, (i.e. Endocrine inactive adenomas, Prolactinomas, and TSH secreting tumors) there were not enough studies identified to allow for rigorous statistical analysis. There is an increasing body of data suggesting that treatment refractory acromegaly and Cushing’s disease puts patients at risk for early mortality, suggesting that aggressive efforts to normalize hormone levels in these patients are justified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Levy A, Lightman S (2003) Molecular defects in the pathogenesis of pituitary tumours. Front Neuroendocrinol 24(2):94–127

    Article  PubMed  CAS  Google Scholar 

  2. Melmed S (2008) Update in pituitary disease. J Clin Endocrinol Metab 93(2):331–338

    Article  PubMed  CAS  Google Scholar 

  3. Chang EF, Sughrue ME, Zada G, Wilson CB, Blevins LS Jr, Kunwar S (2010) Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas. Pituitary 13(3):223–229

    Article  PubMed  Google Scholar 

  4. Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr (2009) Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection. Pituitary 12(3):158–164

    Article  PubMed  CAS  Google Scholar 

  5. DerSimonian R (1990) Combining evidence from clinical trials. Anesth Analg 70(5):475–476

    Article  PubMed  CAS  Google Scholar 

  6. Der Simonian R (1996) Meta-analysis in the design and monitoring of clinical trials. Stat Med 15(12):1237–1248 discussion 1249–1252

    Article  CAS  Google Scholar 

  7. Der Simonian R, Charette LJ, McPeek B, Mosteller F (1982) Reporting on methods in clinical trials. N Engl J Med 306(22):1332–1337

    Article  CAS  Google Scholar 

  8. Der Simonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  Google Scholar 

  9. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411–3418

    Article  PubMed  CAS  Google Scholar 

  10. Arita K, Kurisu K, Tominaga A et al (2003) Mortality in 154 surgically treated patients with acromegaly: a 10-year follow-up survey. Endocr J 50(2):163–172

    Article  PubMed  Google Scholar 

  11. Bates AS, Van’t Hoff W, Jones JM, Clayton RN (1993) An audit of outcome of treatment in acromegaly. Q J Med 86(5):293–299

    PubMed  CAS  Google Scholar 

  12. Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86–91

    Article  Google Scholar 

  13. Biermasz NR, Dekker FW, Pereira AM et al (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89(6):2789–2796

    Article  PubMed  CAS  Google Scholar 

  14. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674

    Article  PubMed  CAS  Google Scholar 

  15. Kauppinen-Makelin R, Sane T, Reunanen A et al (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90(7):4081–4086

    Article  PubMed  Google Scholar 

  16. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. UK acromegaly study group. J Clin Endocrinol Metab 83(8):2730–2734

    Article  PubMed  CAS  Google Scholar 

  17. Swearingen B, Barker FG II, Katznelson L et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426

    Article  PubMed  CAS  Google Scholar 

  18. Trepp R, Stettler C, Zwahlen M, Seiler R, Diem P, Christ ER (2005) Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir 147(3):243–251 discussion 250–241

    Article  CAS  Google Scholar 

  19. Dekkers OM, Biermasz NR, Pereira AM et al (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(3):976–981

    Article  PubMed  CAS  Google Scholar 

  20. Hammer GD, Tyrrell JB, Lamborn KR et al (2004) Transsphenoidal microsurgery for Cushing’s disease: initial outcome and long-term results. J Clin Endocrinol Metab 89(12):6348–6357

    Article  PubMed  CAS  Google Scholar 

  21. Lindholm J, Nielsen EH, Bjerre P et al (2006) Hypopituitarism and mortality in pituitary adenoma. Clin Endocrinol 65(1):51–58

    Article  CAS  Google Scholar 

  22. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 89(4):1613–1617

    Article  PubMed  CAS  Google Scholar 

  23. Etxabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40(4):479–484

    Article  CAS  Google Scholar 

  24. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 41(1):95–102

    Article  CAS  Google Scholar 

  25. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology, long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327–335

    Article  PubMed  CAS  Google Scholar 

  26. Mestron A, Webb SM, Astorga R et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446

    Article  PubMed  CAS  Google Scholar 

  27. Bihan H, Espinosa C, Valdes-Socin H et al (2004) Long-term outcome of patients with acromegaly and congestive heart failure. J Clin Endocrinol Metab 89(11):5308–5313

    Article  PubMed  CAS  Google Scholar 

  28. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89–95

    Article  PubMed  CAS  Google Scholar 

  29. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12(1):71–79

    Article  CAS  Google Scholar 

  30. Nabarro JD (1987) Acromegaly. Clin Endocrinol 26(4):481–512

    Article  CAS  Google Scholar 

  31. Welbourn RB (1985) Survival and causes of death after adrenalectomy for Cushing’s disease. Surgery 97(1):16–20

    PubMed  CAS  Google Scholar 

  32. Watson RG, van Heerden JA, Northcutt RC, Grant CS, Ilstrup DM (1986) Results of adrenal surgery for Cushing’s syndrome: 10 years experience. World J Surg 10(4):531–538

    Article  PubMed  CAS  Google Scholar 

  33. Grabner P, Hauer-Jensen M, Jervell J, Flatmark A (1991) Long-term results of treatment of Cushing’s disease by adrenalectomy. Eur J Surg 157(8):461–464

    PubMed  CAS  Google Scholar 

  34. Favia G, Boscaro M, Lumachi F, D’Amico DF (1994) Role of bilateral adrenalectomy in Cushing’s disease. World J Surg 18(4):462–466

    Article  PubMed  CAS  Google Scholar 

  35. Hoybye C, Grenback E, Rahn T, Degerblad M, Thoren M, Hulting AL (2001) Adrenocorticotropic hormone-producing pituitary tumors: 12–22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49(2):284–291 discussion 291–282

    Article  PubMed  CAS  Google Scholar 

  36. Kobayashi T, Kida Y, Mori Y (2002) Gamma knife radiosurgery in the treatment of Cushing’s disease: long-term results. J Neurosurg 97(5 Suppl):422–428

    PubMed  Google Scholar 

  37. Nagesser SK, van Seters AP, Kievit J et al (2000) Treatment of pituitary-dependent Cushing’s syndrome: long-term results of unilateral adrenalectomy followed by external pituitary irradiation compared to transsphenoidal pituitary surgery. Clin Endocrinol 52(4):427–435

    Article  CAS  Google Scholar 

  38. Sheehan JM, Vance ML, Sheehan JP, Ellegala DB, Laws ER Jr (2000) Radiosurgery for Cushing’s disease after failed transsphenoidal surgery. J Neurosurg 93(5):738–742

    Article  PubMed  CAS  Google Scholar 

  39. Swearingen B, Biller BM, Barker FG II et al (1999) Long-term mortality after transsphenoidal surgery for Cushing’s disease. Ann Intern Med 130(10):821–824

    PubMed  CAS  Google Scholar 

  40. Pikkarainen L, Sane T, Reunanen A (1999) The survival and well-being of patients treated for Cushing’s syndrome. J Intern Med 245(5):463–468

    Article  PubMed  CAS  Google Scholar 

  41. Barker FG II, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the US, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709–4719

    Article  PubMed  CAS  Google Scholar 

  42. Chang EF, Zada G, Kim S et al (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108(4):736–745

    Article  PubMed  Google Scholar 

  43. Tomlinson JW, Holden N, Hills RK et al (2001) Association between premature mortality and hypopituitarism. West midlands prospective hypopituitary study group. Lancet 357(9254):425–431

    Article  PubMed  CAS  Google Scholar 

  44. Bates AS, Bullivant B, Sheppard MC, Stewart PM (1999) Life expectancy following surgery for pituitary tumours. Clin Endocrinol 50(3):315–319

    Article  CAS  Google Scholar 

  45. Sanno N, Teramoto A, Osamura RY (2000) Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg 93(2):194–200

    Article  PubMed  CAS  Google Scholar 

  46. Teramoto A, Sanno N, Tahara S, Osamura YR (2004) Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol 108(2):147–153

    Article  PubMed  CAS  Google Scholar 

  47. Beck-Peccoz P, Persani L (2006) TSH-induced hyperthyroidism caused by a pituitary tumor. Nat Clin Pract Endocrinol Metab 2(9):524–528 quiz following p 528

    Article  PubMed  Google Scholar 

  48. Sanno N, Teramoto A, Osamura RY (2001) Thyrotropin-secreting pituitary adenomas. Clinical and biological heterogeneity and current treatment. J Neurooncol 54(2):179–186

    Article  PubMed  CAS  Google Scholar 

  49. Chanson P, Weintraub BD, Harris AG (1993) Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 119(3):236–240

    PubMed  CAS  Google Scholar 

  50. Caron P, Arlot S, Bauters C et al (2001) Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 86(6):2849–2853

    Article  PubMed  CAS  Google Scholar 

  51. Kuhn JM, Arlot S, Lefebvre H et al (2000) Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 85(4):1487–1491

    Article  PubMed  CAS  Google Scholar 

  52. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P (1996) Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 81(8):3084–3090

    Article  PubMed  CAS  Google Scholar 

  53. Socin HV, Chanson P, Delemer B et al (2003) The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 148(4):433–442

    Article  PubMed  CAS  Google Scholar 

  54. Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD (1999) Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 84(2):476–486

    Article  PubMed  CAS  Google Scholar 

  55. Gesundheit N, Petrick PA, Nissim M et al (1989) Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of 9 patients. Ann Intern Med 111(10):827–835

    PubMed  CAS  Google Scholar 

  56. McCutcheon IE, Weintraub BD, Oldfield EH (1990) Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neurosurg 73(5):674–683

    Article  PubMed  CAS  Google Scholar 

  57. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM (1994) Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 40(3):421–428

    Article  CAS  Google Scholar 

  58. Hankinson SE, Willett WC, Michaud DS et al (1999) Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91(7):629–634

    Article  PubMed  CAS  Google Scholar 

  59. Clayton RN, Stewart PM, Shalet SM, Wass JA (1999) Pituitary surgery for acromegaly. Should be done by specialists. BMJ 319(7210):588–589

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Center for Pituitary Disorders, University of California, 400 Parnassus Avenue, Room A-808, San Francisco, CA, 94143-0350, USA

    Michael E. Sughrue, Edward F. Chang, Rodney A. Gabriel, Manish K. Aghi & Lewis S. Blevins

Authors
  1. Michael E. Sughrue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward F. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rodney A. Gabriel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manish K. Aghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lewis S. Blevins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael E. Sughrue.

Additional information

Michael E. Sughrue and Edward F. Change contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sughrue, M.E., Chang, E.F., Gabriel, R.A. et al. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14, 276–283 (2011). https://doi.org/10.1007/s11102-011-0308-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-011-0308-1

Keywords

Search

Navigation